Dr. Mehta is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Chief Residency, Internal Medicine, 2012 - 2013- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2012
Northwestern University The Feinberg School of MedicineClass of 2009
Certifications & Licensure
IL State Medical License 2020 - 2026
MO State Medical License 2016 - 2025
NY State Medical License 2011 - 2018- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- BV and beyond: how to incorporate novel agents into PTCL management.Imran A Nizamuddin, Neha Mehta-Shah
Hematology. American Society of Hematology. Education Program. 2024-12-06 - 1 citationsValemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka
The Lancet. Oncology. 2024-12-01 - Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.Steven M Horwitz, Ajit J Nirmal, Jahan Rahman, Ran Xu, Esther Drill
Nature Medicine. 2024-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
